⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

May 4, 2024Expert Review of Anti-infective Therapy

Effectiveness of recently-approved oral antiviral medications on the outcome of patients with mild-to-moderate COVID-19 and pre–existing chronic obstructive pulmonary diseases

Bo-Wen Shiau Wan‐Hsuan Hsu Ya‐Wen Tsai Jheng‐Yan Wu Tinghui Liu Po‐Yu Huang Min‐Hsiang Chuang Chih-Cheng Lai Lih-Wen Jang

View Full Paper

Ask AI

Bookmark

Share

Abstract

Objectives This study assessed the effectiveness of the oral antiviral agents nirmatrelvir – ritonavir (NMV-r) and molnupiravir (MOV) for treating mild-to-moderate coronavirus disease 2019 (COVID-19) in patients with COPD.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Shiau et al. (2024) studied this question.

synapsesocial.com/papers/68e6b925b6db643587639e40 https://doi.org/10.1080/14787210.2024.2351571

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Clinical effectiveness of oral antiviral agents for treating non-hospitalized COVID-19 patients with chronic kidney disease2024 · 3 citations
2The effectiveness of novel oral antiviral treatment for non-hospitalized high-risk patients with COVID-19 during predominance of omicron XBB subvariants2024 · 4 citations
3The effect of oral antiviral therapy for COVID-19 in managing non-hospitalized patients with lung cancer2024
4Effectiveness of oral antivirals in reducing adverse outcomes in asthmatic patients with non-severe COVID-19: A multi-institutional retrospective cohort studyCohort Study · 2026
5Effectiveness of molnupiravir for the treatment of COVID-19: a systematic literature review of real-world observational studies2025